A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study

Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D 2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy

“…During 97 (85.8%) of the cycles patients had no emetic episodes on days 1 through 5. This result is even comparable with those obtained in trials with both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19][20] used as single agents or in combination [14,20] in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.…”

“…In accordance with other studies, the protection against nausea was less effective than the protection against emetic episodes [13][14][15][16][17][18][19], but for protection from nausea the efficacy of granisetron plus prednisolone plus metopimazine is also comparable to that of both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19] used as single agents during the first cycle of moderately emetogenic chemotherapy.…”

Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D 2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy

“…During 97 (85.8%) of the cycles patients had no emetic episodes on days 1 through 5. This result is even comparable with those obtained in trials with both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19][20] used as single agents or in combination [14,20] in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.…”

“…In accordance with other studies, the protection against nausea was less effective than the protection against emetic episodes [13][14][15][16][17][18][19], but for protection from nausea the efficacy of granisetron plus prednisolone plus metopimazine is also comparable to that of both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19] used as single agents during the first cycle of moderately emetogenic chemotherapy.…”

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

“…Granisetron was superior to the combination of prednisolone plus metopimazine in the treatment of acute nausea and vomiting during the first cycle of chemotherapy. CR on day 1 was obtained in 68.8% of the patients treated with granisetron in accordance with the results in other trials investigating a 5-hydroxytryptamine 3 (5-HT 3 ) antagonist (Bonneterre et al, 1990;Kaasa et al, 1990;Marty, 1990;Jones et al, 1991;Marschner et al, 1991;Warr et al, 1991;Italian Group for Antimetic Research, 1995b). When the trial was initiated granisetron was available in Denmark for intravenous use only.…”

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

“…This is at least as good as earlier trials where patients receiving non-cisplatin CT treated with OND alone obtained control rates form 65-82% (6)(7)(8)(9).…”

Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D 2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy

“…During 97 (85.8%) of the cycles patients had no emetic episodes on days 1 through 5. This result is even comparable with those obtained in trials with both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19][20] used as single agents or in combination [14,20] in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.…”

“…In accordance with other studies, the protection against nausea was less effective than the protection against emetic episodes [13][14][15][16][17][18][19], but for protection from nausea the efficacy of granisetron plus prednisolone plus metopimazine is also comparable to that of both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19] used as single agents during the first cycle of moderately emetogenic chemotherapy.…”

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

“…Granisetron was superior to the combination of prednisolone plus metopimazine in the treatment of acute nausea and vomiting during the first cycle of chemotherapy. CR on day 1 was obtained in 68.8% of the patients treated with granisetron in accordance with the results in other trials investigating a 5-hydroxytryptamine 3 (5-HT 3 ) antagonist (Bonneterre et al, 1990;Kaasa et al, 1990;Marty, 1990;Jones et al, 1991;Marschner et al, 1991;Warr et al, 1991;Italian Group for Antimetic Research, 1995b). When the trial was initiated granisetron was available in Denmark for intravenous use only.…”

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

“…This is at least as good as earlier trials where patients receiving non-cisplatin CT treated with OND alone obtained control rates form 65-82% (6)(7)(8)(9).…”

Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D 2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy

“…During 97 (85.8%) of the cycles patients had no emetic episodes on days 1 through 5. This result is even comparable with those obtained in trials with both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19][20] used as single agents or in combination [14,20] in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.…”

“…In accordance with other studies, the protection against nausea was less effective than the protection against emetic episodes [13][14][15][16][17][18][19], but for protection from nausea the efficacy of granisetron plus prednisolone plus metopimazine is also comparable to that of both a corticosteroid [13,14] and a 5-HT 3 antagonist [13][14][15][16][17][18][19] used as single agents during the first cycle of moderately emetogenic chemotherapy.…”

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

“…Granisetron was superior to the combination of prednisolone plus metopimazine in the treatment of acute nausea and vomiting during the first cycle of chemotherapy. CR on day 1 was obtained in 68.8% of the patients treated with granisetron in accordance with the results in other trials investigating a 5-hydroxytryptamine 3 (5-HT 3 ) antagonist (Bonneterre et al, 1990;Kaasa et al, 1990;Marty, 1990;Jones et al, 1991;Marschner et al, 1991;Warr et al, 1991;Italian Group for Antimetic Research, 1995b). When the trial was initiated granisetron was available in Denmark for intravenous use only.…”

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

“…This is at least as good as earlier trials where patients receiving non-cisplatin CT treated with OND alone obtained control rates form 65-82% (6)(7)(8)(9).…”